FKRP and cancer: We therefore hypothesize that ribitol treatment of the cancer cells increases CDP-ribitol which in turn improves efficiency of normal FKRP (confirmed by sequencing and the data is included in the Supplementary Information Fig. 6), and possibly FKTN, and thus the levels of matriglycan synthesis.